A group of International experts chaired by Abraham Morgenthaler, a U.S. urologist affiliated with Harvard Medical School, have come to a consensus regarding the diagnosis and treatment of low testosterone. They present nine Resolutions and provide discussion and conclusions that help dispel many of the myths surrounding testosterone and its use as well as solidify knowledge accumulated since the 1950’s regarding testosterone’s benefits.
A brief summary of the Resolutions is below and the full article printed in the Mayo Clinic Proceedings, July 2016, Volume 91, Issue 7, Pages 881–896 can be found at the following link: Mayo Clinic Proceedings.
- TD is a well-established, clinically significant medical condition that negatively affects male sexuality, reproduction, general health and quality of life.
- Symptoms and signs of TD occur as a result of low levels of testosterone and may benefit from treatment regardless of whether there is an identified underlying origin.
- TD is a global public health concern.
- Testosterone therapy for men with TD is effective, rational, and evidence-based.
- There is no testosterone concentration threshold that reliably distinguishes those who will respond to treatment from those who will not.
- There is no scientific basis for any age-specific recommendations against the use of testosterone therapy in adult males.
- The evidence does not support increased risks of cardiovascular events with testosterone therapy.
- The evidence does not support increased risk of prostate cancer with testosterone therapy.
- The evidence supports a major research initiative to explore possible benefits of testosterone therapy for cardiometabolic disease, including diabetes.